This, too, supports the presence of at least a subset of patients exhibiting reduced stimulus-activity coupling at CCK1R, with some of these patients typical of those who were likely included in previous clinical trials for the treatment of obesity. This evidence concerns the gene CCKAR and obesity due to melanocortin 4 receptor deficiency.